Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects

Zancong Shen,1 Michael Gillen,2 Jeffrey N Miner,1 Gail Bucci,1 David M Wilson,1 Jesse W Hall1 1Ardea Biosciences, Inc., San Diego, CA, 2AstraZeneca, Gaithersburg, MD, USA Purpose: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout a...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkkit: Shen Z (Dahkki), Gillen M (Dahkki), Miner JN (Dahkki), Bucci G (Dahkki), Wilson DM (Dahkki), Hall JW (Dahkki)
Materiálatiipa: Girji
Almmustuhtton: Dove Medical Press, 2017-07-01T00:00:00Z.
Fáttát:
Liŋkkat:Connect to this object online.
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

Connect to this object online.

3rd Floor Main Library

oažžasuvvan: 3rd Floor Main Library
Hildobáiki: A1234.567
Njađus 1 Oažžumis